- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01093092
Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
A Phase I Clinical Trial of Oral Calcitriol With Fixed Dose of Cisplatin and Gemcitabine in Patients With Advanced Solid Tumors
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose of oral calcitriol when combined with a standard dose of gemcitabine (gemcitabine hydrochloride) and cisplatin in a 28-day cycle.
SECONDARY OBJECTIVES:
I. Describe the toxicity of this combination using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
II. Study the pharmacokinetics of calcitriol at the maximum tolerated dose (MTD) in an expanded cohort of 6 patients.
III. Describe the clinical activity associated with this regimen in this advanced solid tumor population.
OUTLINE:
Patients receive calcitriol orally (PO) on days 1, 2, 8, 9, 15 and 16; cisplatin intravenously (IV) over 2 hours on day 2; and gemcitabine hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
New York
-
Buffalo, New York, Stati Uniti, 14263
- Roswell Park Cancer Institute
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22903
- Emily Couric Clinical Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients with a diagnosis of advanced unresectable non-hematological malignancy that has no known standard of care or for which the use of gemcitabine plus cisplatin constitutes a reasonable option
- Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- White blood cell (WBC) >= 3.0 x 10^9/L
- Neutrophils >= 1.5 x 10^9/L
- Platelets >= 100 x 10^9/L
- Hemoglobin (Hgb) >= 10 g/dL
- Bilirubin =< institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x institutional ULN unless metastatic to liver in which case AST and ALT should be < 5 x institutional ULN
- Creatinine =< 1.5 x institutional ULN
- Corrected calcium =< institutional ULN (corrected calcium = (4- Albumin) x 0.8 + calcium)
- Patients of child-bearing potential must agree to use acceptable contraceptive methods (e.g., double barrier) during treatment
- Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
- No treatment with investigational agents within 4 weeks prior to study drug administration, except patients receiving targeted therapies such as kinase inhibitors with half-lives < 48 hours may be treated if > 14 days have elapsed after the last dose and related toxicities have recovered to =< grade 1
- No chemotherapy within 4 weeks prior to study treatment administration; nitrosoureas and mitomycin C are not allowed within 6 weeks prior to initiation of study treatment
- Palliative radiation, including whole brain radiation therapy (WBRT), is allowed prior to enrollment as long as it is completed > 2 weeks from initiation of study treatment, and provided patient has recovered from treatment toxicities to =< grade 1
- Patients should be able to take oral medications
Exclusion Criteria:
- Known hypersensitivity to any of the study drugs involved
- Brain metastases are excluded unless treated and shown to be controlled more than 1 month from after craniotomy or more than 2 weeks after gamma knife radiosurgery and not associated with central nervous system (CNS) symptoms
- History of clinically significant hypercalcemia
- Evidence of nephrectomy
- History of (within 24 months prior to enrollment) of kidney, ureter, or bladder stones with clinically significant sequelae (e.g. (painless gross hematuria; pain with or without infection; hydronephrosis, etc); patients with otherwise stable non-occluding kidney stones regardless of stone type incidentally found in computed tomography (CT) scans are eligible; patients with prior history of uric acid stones are eligible regardless of time of onset
- Unwillingness to stop calcium supplementation (during the first cycle of treatment) or vitamin D supplementation throughout the study
- Thiazide (e.g HCTZ, Hydrochoirthiazide) or digoxin therapy (e.g Lanoxicaps, Lanoxin)
- Pregnant or nursing female patients.
- Unwilling or unable to follow protocol requirements
- Any condition which in the investigator's opinion deems the patient an unsuitable candidate to receive study drug
- Received an investigational agent within 4 weeks prior to enrollment, except patients receiving targeted therapies such as kinase inhibitors with half-lives < 48 hours may be treated if > 14 days have elapsed after the last dose and related toxicities have recovered to =< grade 1
- Nut allergy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Treatment (calcitriol, cisplatin, gemcitabine hydrochloride)
Patients receive calcitriol PO on days 1, 2, 8, 9, 15 and 16; cisplatin IV over 2 hours on day 2; and gemcitabine hydrochloride IV over 30 minutes on days 2, 9, and 16.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Studi correlati
Altri nomi:
Dato IV
Dato IV
Altri nomi:
Dato PO
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
MTD of oral calcitriol when combined with a standard dose of gemcitabine hydrochloride and cisplatin, determined according to incidence of dose-limiting toxicity, graded using the National Cancer Institute (NCI) CTCAE version 4.0
Lasso di tempo: 28 days
|
A standard 3+3 with de-escalation will be used to estimate the MTD.
|
28 days
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Toxicity of this combination, graded according to NCI CTCAE version 4.0
Lasso di tempo: Up to 30 days after last dose of study drug
|
Tabulated overall or by dose level (as appropriate).
|
Up to 30 days after last dose of study drug
|
Pharmacokinetic (PK) analyses of calcitriol at the MTD in an expanded cohort of 6 patients, including peak levels, area under the concentration-time curve from time 0-72 hours, terminal half-life, volume of distribution, and total body clearance
Lasso di tempo: Days 1-3 of course 1
|
PK data will be presented as plots of serum calcitriol concentration over time for each patient.
An assessment of whether systemic calcitriol exposure associated with antitumor activity in preclinical models is achieved in these patients will be made.
|
Days 1-3 of course 1
|
Objective tumor response, described using Response Evaluation Criteria in Solid Tumors 1.1
Lasso di tempo: Up to 5 years
|
Responses tabulated as appropriate.
|
Up to 5 years
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Grace Dy, Roswell Park Cancer Institute
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Agenti antinfettivi
- Agenti antivirali
- Inibitori enzimatici
- Antimetaboliti, Antineoplastici
- Antimetaboliti
- Agenti antineoplastici
- Agenti immunosoppressivi
- Fattori immunologici
- Micronutrienti
- Modulatori di trasporto a membrana
- Vitamine
- Agenti di conservazione della densità ossea
- Ormoni e agenti regolatori del calcio
- Agenti vasocostrittori
- Agonisti dei canali del calcio
- Gemcitabina
- Calcitriolo
- Diidrossicolecalciferoli
Altri numeri di identificazione dello studio
- I 163509 (Altro identificatore: Roswell Park Cancer Institute)
- P30CA016056 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-2010-00263 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Neoplasia solida dell'adulto
-
AstraZenecaReclutamentoAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, carcinoma gastrico, mammario e ovaricoSpagna, Stati Uniti, Belgio, Regno Unito, Francia, Ungheria, Canada, Corea, Repubblica di, Australia
Prove cliniche su Studio farmacologico
-
Digisight Technologies, Inc.SconosciutoRetinopatia diabetica | Degenerazione maculare legata all'età | MetamorfopsiaStati Uniti
-
University of MichiganCompletato
-
University of MichiganCompletatoTelemedicinaStati Uniti
-
St. Joseph's Healthcare HamiltonSospeso
-
AstraZenecaCompletatoCancro al seno | Oncologia | EpidemiologiaAlgeria
-
University of MichiganAttivo, non reclutanteDepressione | Attività fisica | Sonno | Stato d'animoStati Uniti
-
Fonds de la Recherche en Santé du QuébecUniversité de MontréalCompletatoIpertensione | Diabete mellito, tipo 2 | Dislipidemie | Colesterolo, LDL | ComorbiditàCanada
-
University of MichiganCompletatoDepressione | Attività fisica | Sonno | Stato d'animoStati Uniti
-
Peking UniversityHuantai Maternal and Child Health Care HospitalSconosciutoDisfunzione gastrointestinale | Disturbi della nutrizione infantileCina
-
University of HawaiiNational Cancer Institute (NCI); National Institutes of Health (NIH); University...Reclutamento